Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech’s shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target boost from an analyst.
That professional is Stifel Financial‘s Alex Thompson, who upped his fair-value assessment of Aclaris to $20 per share. That’s exactly 25% higher than his previous estimation of $16. In making the change, Thompson maintained his buy recommendation on the biotech.
It wasn’t immediately clear why Thompson made his move, but it isn’t hard to be bullish on Aclaris’ future these days. The summer months saw the company move forward in the development of its leading investigational drug, zunsemetinib, which targets moderate to severe cases of rheumatoid and psoriatic arthritis.
During the period, the company also delivered second-quarter results that beat — albeit slightly — analysts’ bottom-line expectations and came close to hitting the collective revenue estimate.
More encouragingly, the biotech said that it had nearly $211 million in cash, equivalents, and marketable securities as of the end of June. According to its forecasts, this is sufficient to fund operations through the end of 2025.
For clinical-stage biotechs like Aclaris, investors are hungry to see progress in key pipeline drug programs. They also like it when the funding that supports their investments is robust.
At the moment, Aclaris is ticking both boxes, giving it a decent chance to carry zunsemetinib through to the completion of its development process — not to mention the other products the company has in the pipeline.
10 stocks we like better than Aclaris Therapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Aclaris Therapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 11, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
